The FDA granted accelerated approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) to treat hepatocellular carcinoma (HCC) in patients who have been treated with sorafenib (Nexavar, Bayer).
The expanded indication for this combination was based on results from the phase 1/2 CheckMate 040 trial (ClinicalTrials.gov Identifier: NCT01658878) in the cohort treated with nivolumab plus ipilimumab after sorafenib.